- Mixed-methods pilot randomised controlled trial of 24 adults with knee osteoarthritis, combining quantitative feasibility data with semi-structured interviews.
- Participants were assigned to active or sham home-based tDCS plus an eight-week exercise program, with 10 stimulation sessions over two weeks.
- Adherence was high: 21/24 (88%) completed at least 75% of tDCS sessions, and no significant adverse events occurred. Mean pain intensity fell in both groups by week 8, from 47.3 to 28.3 (active) and 46.4 to 33.5 (sham).
- The authors concluded the approach was feasible, acceptable and well tolerated, and that a fully powered trial of 80 participants is warranted to test effects on pain and function.
Chronic pain
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Open-label multicentre randomised trial across 15 UK thoracic centres included 737 adults undergoing thoracotomy in the modified intention-to-treat population.
- The paravertebral group received three single-shot injections before incision plus a catheter, compared with a thoracic epidural catheter loaded with local anaesthetic before incision.
- Chronic post-thoracotomy pain at six months did not differ significantly, at 22% versus 16% (adjusted RR 1.32, 95% CI 0.93 to 1.86, P=0.12).
- Paravertebral blockade had less hypotension (12% vs 18%) and pruritus but more urinary retention (12% vs 6%), and day 1 acute pain was higher with paravertebral blockade.
AI summary not available. Read the source abstract on PubMed.
AI summary not available. Read the source abstract on PubMed.
- Randomized controlled trial of 90 healthy female participants, assigned to an open-label placebo group with choice, an open-label placebo group without choice, or a no-placebo control.
- Perceived pain was measured with transcutaneous electrical stimulation at baseline and after open-label placebo treatment or a waiting period.
- Open-label placebo reduced reported pain whether or not participants could choose the placebo type, and the choice group showed no preference for capsules, sprays, or colors.
- Higher positive superstition was linked to greater pain reduction in the placebo groups, while higher reported pain sensitivity showed the opposite pattern.
- Randomized equivalence trial of 84 adults with chronic non-specific low back pain and probable nociplastic features, conducted at a single rehabilitation department.
- Participants received weekly IV lidocaine (1 mg/kg bolus, then 4 mg/kg infusion over 4 weeks) or saline placebo, with all receiving amitriptyline and aerobic exercise.
- At 3 months, the VAS difference was 0.24 (90% CI -0.33 to 0.81), within the prespecified ±1.5 equivalence bounds (TOST P < .001); sleep quality favored lidocaine (mean difference 1.81; 95% CI 0.49-3.14; P = .027).
- The authors concluded lidocaine gave no additional analgesia over saline alongside multimodal care, and adverse events were more frequent with lidocaine but mild and transient.
AI summary not available. Read the source abstract on PubMed.
- Phase 2b randomized, double-blind, placebo-controlled dose-ranging trial in 110 participants after third molar extraction.
- Oral meloxicam formulation MR-107A-02 given at 1.25, 5, or 15 mg twice daily was compared with placebo.
- Mean SPID0-24 Emax values were 70.7, 86.7, and 94.8 across the doses, versus 52.0 for placebo; 5 and 15 mg were significant (p < .001).
- The 15 mg dose gave perceptible relief at 0.6 hours and meaningful relief at 1.5 hours, with the lowest rescue use (29.6%); authors report good tolerability.
- Secondary analysis of baseline data from 685 participants pooled from two clinical trials, with 44% living in rural areas and 96% female.
- Rurality and sociodemographic characteristics were examined as baseline factors associated with fibromyalgia severity and other symptom measures.
- FIQR was associated with age, race, marital status, education, employment, and income but not rurality (t = -0.350, P = 0.726), and sociodemographics explained R2 = 0.09 of FIQR variance.
- The authors conclude that sociodemographic factors and rurality had limited influence on fibromyalgia severity, pain, fatigue, and pain catastrophizing.
- Randomized within-patient trial of 48 adults (96 leads) receiving bilateral thoracic percutaneous spinal cord stimulator trial leads at one academic center.
- One lead in each patient was randomly anchored with Dermabond and the contralateral lead with suture, and upright radiographic migration was compared.
- Mean absolute migration was 9.15 mm with Dermabond versus 10.60 mm with suture (paired difference -1.46 mm, 95% CI -6.73 to 3.81; P = .58).
- Male sex and prior spine surgery predicted more migration, while fixation method did not; the authors call Dermabond clinically comparable to suture.
- Multicentre, randomised, double-blind trial in 873 analysed adults (914 randomised) undergoing video-assisted thoracoscopic lung resection.
- Perioperative low-dose esketamine (bolus at induction, then intra- and postoperative infusion for 48 h) was compared with normal saline.
- Chronic pain at 3 months was 14.7% with esketamine versus 21.2% with control (adjusted OR 0.62, 95% CI 0.43-0.90; P=0.013).
- A post hoc definition using NRS ≥3 during coughing also favoured esketamine (adjusted OR 0.39, 95% CI 0.19-0.84; P=0.015), and the authors report no increase in adverse effects.
- Randomized, double-blind, placebo-controlled crossover trial in 30 patients with chronic post-surgical peripheral neuropathic pain at a French university hospital.
- Participants took oral therapeutic-dose acetaminophen (3 g/day) or placebo for 7 days each, separated by a 7-day washout.
- Mean pain intensity did not differ from placebo (effect size -0.09, 95% CI -0.45 to 0.26, P = 0.607), and no secondary outcomes differed.
- The authors found no clinically meaningful short-term add-on analgesic benefit and no adverse events, and advised informing patients about the risks of long-term use.
- Pilot randomized, triple-blind trial of 36 patients undergoing bilateral total knee arthroplasty, split evenly across placebo, 400 mg, and 800 mg oral CBD groups.
- Four perioperative doses of oral CBD were compared with placebo, all given alongside standardized anesthesia and multimodal analgesia.
- Dunnett's testing found no significant difference in 72-hour opioid use versus placebo (400 mg: 144 vs 209 MME, p=0.10; 800 mg: 203.2 vs 209 MME, p=0.98).
- Post hoc testing showed lower opioid use with 400 mg (p=0.04), and the authors frame the findings as a potential signal that needs larger trials.
AI summary not available. Read the source abstract on PubMed.
- Single-blind randomized trial of 120 women aged 20-50 with mild to moderate chronic nonspecific low back pain, comparing three arms over 8 weeks.
- Compared CFT combined with Pilates against Pilates alone and a control group, with pain intensity as the primary outcome.
- Both Pilates-based arms outperformed control on pain, disability, and kinesiophobia, but CFT added no difference to Pilates for pain (p = 0.871) or disability (p = 1.000).
- CFT plus Pilates was superior for kinesiophobia (p = 0.001), trunk flexion endurance (p = 0.003), and lateral-flexion endurance (p = 0.001).
- Randomised, quadruple-blind trial of 90 patients aged 65-100 undergoing primary total knee arthroplasty, comparing dexamethasone adjuncts to adductor canal and iPACK blocks.
- Perineural dexamethasone (4 mg total, 2 mg per block) with ropivacaine was compared with intravenous dexamethasone 4 mg and with placebo.
- Median time to first rescue opioid was 4.5 h with placebo, 13.9 h with IV dexamethasone and 18.5 h with perineural dexamethasone (log-rank p < 0.001).
- Perineural dexamethasone produced lower opioid use than IV at later timepoints, and no motor weakness or nerve injury was reported.
- Randomized crossover trial of 48 people with nonspecific shoulder pain, comparing a blood flow restriction session with a sham-BFR session after a 7-day washout.
- Each session used low-load biceps curls with either BFR or sham-BFR, followed by a standardized shoulder exercise loading session.
- BFR produced larger immediate MVIC gains (EMD = 0.058, p < 0.05) and larger gains after loading (EMD = 0.042, p < 0.05) than sham; PPT rose only after BFR (infraspinatus EMD = 1.32; middle deltoid EMD = 1.27).
- The authors conclude that a single BFR session gave immediate, clinically meaningful pain reduction and strength gains, though both conditions reduced pain.
- Randomized trial of 302 adults with chronic low back pain across three arms (behavioral activation, cognitive therapy, mindfulness meditation), using twice-daily ecological momentary assessment and daily activity monitoring.
- The study tested whether changes in pain catastrophizing, mindful nonjudgment, and activity level accounted for improvement in pain interference, during and after treatment.
- All three treatments improved pain interference, catastrophizing, and nonjudgment with no between-treatment differences, but activity level did not change.
- Structural equation models found mostly nonsignificant cross-lagged effects, though outcome and mechanism changes were correlated, and the authors favored a shared mechanisms model.
- Randomized, double-blind, sham-controlled feasibility trial at one US government hospital enrolled 48 veterans with fibromyalgia, with 47 analyzed.
- Participants self-administered in-home cranial electrotherapy stimulation or sham for 60 minutes daily over 12 weeks, with resting-state fMRI at baseline, 6, and 12 weeks.
- Both groups improved versus baseline at 12 weeks, including DVPRS pain (-1.88 ± 2.2), with significant between-group differences only for sleep interference (P = .04).
- Authors report similar pain and functional improvement in both arms, and imaging showed differential cerebellar-visual connectivity changes, supporting feasibility of larger trials.
- Randomized crossover study of 60 healthy women (mean age 25.13) exposed to capsaicin-induced acute thermal pain across two virtual reality sessions.
- The experimental arm received VR-based Interoceptive Modeling, compared with a control arm receiving VR pain visualization without the interoceptive modeling component, separated by a one-week washout.
- Pain intensity was lower in the experimental condition (Mdiff=5.30, 95% CI 0.34-10.27, p=.037), and immediate post-intervention RMSSD was higher (Mdiff=6.97, 95% CI 3.12-10.83, p<.001).
- The authors describe Interoceptive Modeling as a promising non-pharmacological approach but state that further research is needed.
AI summary not available. Read the source abstract on PubMed.
- This two-stage adaptation study used established frameworks, combining an adaptation working group, evidence review, interest-holder engagement and expert consultation to adapt the RESOLVE program for chronic low back pain.
- Stage 2 used a structured consensus meeting to propose and finalise adaptations to the intervention's content, delivery, resources and clinician training.
- The consensus process finalised 8 adaptations that refine and streamline existing RESOLVE components rather than removing or adding whole elements.
- The authors present the approach as practical guidance for adapting RESOLVE and other complex treatments for clinical implementation, though the adapted program's effects were not reported.
- Randomized, placebo-controlled, double-blinded crossover-style study in 20 healthy participants testing topical drugs on peripheral sensory nerve excitability.
- Compared topical 5% lidocaine, 10% phenytoin and 2% mepyramine against placebo, measuring perception threshold changes with a new sodium channel nociceptor testing protocol.
- Perception threshold increases differed between drugs (P < 0.01) and versus placebo (P < 0.01), except phenytoin (P = 0.22), which did not differ significantly.
- Authors report a computational model suggesting lidocaine and mepyramine alter Nav1.7, 1.8 and 1.9 currents differently, supporting the protocol for probing subtype-specific pharmacology.
- Double-blind randomized controlled trial of 115 Veterans with chronic low back pain and prescription opioid misuse (NCT02483468).
- Participants received either real or sham transcranial direct current stimulation during 11 sessions of Cognitive Behavioral Therapy for Chronic Pain.
- Real stimulation showed significant time-by-group interactions for pain and functional impairment, with a steeper decline than sham.
- Opioid misuse decreased over time in both groups with no added benefit from stimulation, and the authors describe it as a promising adjunct.
- Randomized, double-blind trial of 90 patients with lumbar disc herniation at a tertiary care center.
- Compared intradiscal ozone therapy with percutaneous lumbar nucleoplasty, assessing pain (VAS), disability (ODI), and quality of life (SF-36) at baseline, 1 month, and 12 months.
- Both groups improved significantly on VAS and ODI at 1 and 12 months (P < 0.001), with nucleoplasty showing lower scores than ozone at both time points.
- The authors conclude both procedures are effective and that nucleoplasty has superior long-term outcomes, though the abstract reports no effect sizes or confidence intervals.
- Randomized trial of 60 patients with diabetic peripheral neuropathic pain at one hospital in China, split into curved-needle (n=30) and straight-needle (n=30) lumbar sympathetic radiofrequency ablation groups.
- The comparison was curved-needle versus straight-needle technique for lumbar sympathetic ganglion radiofrequency ablation, both guided by ultrasound and fluoroscopy and combined with anhydrous ethanol.
- The curved needle group had shorter procedure time (10.6 ± 3.1 vs 15.2 ± 2.3 min, P < 0.001), fewer needle redirections (0.5 vs 4.5) and fewer bone contacts (1.0 vs 4.0), all P < 0.001.
- Success rate (96.7% vs 90.0%, P = 0.611), VAS pain scores and complications (3.33% vs 13.33%, P = 0.357) did not differ significantly, and the authors report higher satisfaction with the curved needle.
- Randomized, double-blind, placebo-controlled trial of 180 patients with moderate-to-severe knee osteoarthritis (Kellgren-Lawrence 3 or 4) at a single Indian tertiary pain clinic.
- Patients received three intraarticular injections, every 3 weeks, of hypertonic dextrose, ozone, and magnesium (Prolozone M), compared with corticosteroid or saline.
- At 24 weeks, WOMAC pain improved more than with corticosteroid (mean change -2.3, 98.3% CI -3.8 to -0.8, P<0.001, d 0.88); saline comparison is not reported in the abstract.
- The authors conclude the therapy is safe and provides clinically relevant analgesia, with early signs of chondroprotection on radiographs.
- Prospective, randomized, single-center trial of 90 adults (89 completed) undergoing elective laparoscopic cholecystectomy, allocated to single-injection, multi-injection, or no-block groups.
- Ultrasound-guided unilateral subcostal TAP block was given as a single injection or as multiple injections, compared with no block.
- The multi-injection group had the lowest 24-hour tramadol use and lower VAS scores at 1, 6, and 24 hours (P<0.05), with PONV-free rates of 92% vs 64% vs 52% (P=0.007).
- The authors conclude both block types gave effective analgesia, with the multi-injection technique showing superior pain control and higher patient satisfaction (P<0.001).
- A single-center randomized controlled trial in Iran enrolled 90 patients with carpal tunnel relapse after surgery, split into three groups of 30 and followed for 12 months.
- Patients received ultrasound-guided hydrodissection with hyaluronidase 300 IU, hypertonic saline 5%, or normal saline, each combined with methylprednisolone and bupivacaine.
- All groups improved, but the hyaluronidase group had significantly greater reductions in VAS and Symptom Severity Scale scores at every follow-up (P < 0.01).
- Hyaluronidase also required fewer reinjections and reported the highest satisfaction, while hypertonic and normal saline did not differ significantly.
- Randomized trial of 451 adults with chronic low back pain recruited from primary care clinics in Massachusetts, Pennsylvania, and North Carolina, randomized 1:1.
- Participants received an 8-week telehealth-delivered mindfulness group medical visit program or usual care.
- At 6 months, PEG scores improved more with the intervention (between-group difference -0.62, 95% CI -1.02 to -0.23; P = .002), but the prespecified 1-point MCID was not met at any time point.
- Significant between-group differences were also reported at 8 weeks and 12 months, and the authors describe the program as scalable and nonpharmacologic.
- Randomized controlled trial of 84 women with fibromyalgia, assigned to music therapy (n=42) or brainwave entrainment via a BrainTap headset (n=42), with 6-month follow-up.
- Brainwave entrainment was given for 20 minutes daily, 5 days a week, for 8 weeks, and was compared against music therapy delivered on the same schedule.
- The brainwave entrainment group reduced pain on the VAS and the McGill pain questionnaire PRI total score (P = .0001), with no confidence intervals reported.
- The authors conclude that brainwave entrainment may relieve pain and improve quality of life, possibly through lower oxidative stress and BDNF levels, though music therapy also improved some measures.
- Double-blinded randomized phase I/II trial of 58 participants with radicular pain from lumbosacral spinal stenosis.
- Transforaminal injection of sterile amniotic fluid filtrate was compared with dexamethasone, with safety and pain and function outcomes followed to 6 months.
- At 3 months, more dexamethasone patients had at least 50% pain reduction: back 45.8% vs 15.0% (P=.050) and leg 60.0% vs 25.0% (P=.034).
- Adverse event rates were comparable between groups with no serious intervention-related events, and the trial was stopped early after dexamethasone showed greater benefit.
AI summary not available. Read the source abstract on PubMed.
- Multicenter randomized controlled trial of 48 patients with lumbar spinal stenosis, reporting outcomes out to five years.
- Interspinous fixation device (IFD) with indirect decompression was compared with standard open direct decompression; five-year data were reported for 18 IFD and 25 decompression patients.
- At five years, the IFD group improved significantly on ODI (-53%), VAS-leg (-66%), VAS-back (-60%) and ZCQ (-29%); decompression improved on three of four measures, not VAS-leg (-64%).
- The authors report comparable overall clinical success and favorable IFD perioperative metrics, including 80% less blood loss, but describe the comparisons as exploratory.
- Randomized, sham-controlled, double-blind trial of 94 adults with chronic neuropathic pain, with responders and nonresponders followed in later parts.
- Five days of prolonged continuous theta burst stimulation (pcTBS), 10-Hz rTMS, or sham over left M1; nonresponders then received left DLPFC stimulation.
- Both active M1 groups reduced pain from baseline (10-Hz 37.9 ± 17.5 vs 48.5 ± 16.0, P < .001; pcTBS 35.1 ± 15.3 vs 47.1 ± 15.1, P < .001), with no difference between them (P = .16).
- pcTBS produced faster corticospinal excitability changes than sham (MEP 188.5 ± 39.8 vs 102.2 ± 6.9, P = .044). The authors conclude pcTBS is comparable to 10-Hz rTMS with substantially less treatment time.
- Secondary longitudinal mediation analysis of a 3-arm randomized trial (N = 223) in chronic low back pain, pooling 8-session CBT and 1-session Empowered Relief versus 1-session health education.
- Latent growth curve models tested whether changes in pain intensity, interference, catastrophizing, and self-efficacy over 3 months mediated improvements in sleep.
- Reductions in pain interference and catastrophizing were linked to indirect pathways to better sleep, while pain intensity was not, and self-efficacy showed a partial pathway.
- The authors suggest that targeting pain interference and pain-related cognitions may produce benefits across both sleep and pain; the abstract reports no effect sizes or confidence intervals.
- Prospective quasi-randomized controlled trial of 109 patients with persistent pain after knee arthroplasty, assigned by procedure group to genicular nerve treatment.
- Compared conventional radiofrequency thermocoagulation (RFT) with chemical neurolysis using phenol of the genicular nerves.
- Phenol had lower NRS at 1 month (3.67 vs 4.09, p=0.015) and 6 months (5.02 vs 6.52, p<0.001); 6-month ≥50% improvement was 43.6% vs 18.5% (p=0.005).
- Authors conclude both treatments are effective for persistent post-arthroplasty pain, complications were similar (5.5% vs 3.7%), and phenol's short-term benefit needs long-term confirmation.